---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000017"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:26:12.607360+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allogene reports Q4 2022 net loss $94.8M, cash $576.5M; pipeline advances

## Summary
- Net loss Q4 2022 $94.8M ($0.66/share); full year net loss $332.6M ($2.32/share).
- Cash, cash equivalents and investments $576.5M as of Dec 31, 2022; expects 2023 cash burn ~$250M, runway into 2025.
- Initiated ALPHA2 Phase 2 trial of ALLO-501A in R/R LBCL; enrollment expected to complete 1H 2024.
- Phase 1 data: ALLO-501A single dose FCA90 showed 67% ORR, 58% CR rate, median DoR 23.1 months.
- UNIVERSAL trial of ALLO-715 in R/R MM: 67% ORR, 42% VGPR+ rate, median DoR 9.2 months.

## SEC filing metadata
- accession: 0001737287-23-000017
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000017/0001737287-23-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000017/allo-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000017
- JSON: https://secwatch.observer/filing/0001737287-23-000017.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000017.txt

## Key facts
- Earnings Releases
  Allogene Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2022.
  - Period: fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 28, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000017/0001737287-23-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.